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Background: Around one third to one half of patients with hip fractures require red-cell pack transfusion. The
increasing incidence of hip fracture has also raised the need for this scarce resource. Additionally, red-cell pack
transfusions are not without complications which may involve excessive morbidity and mortality. This makes it
necessary to develop blood-saving strategies. Our objective was to assess safety, efficacy, and cost-effictveness of
combined treatment of i.v. ferric carboxymaltose and erythropoietin (EPOFE arm) versus i.v. ferric carboxymaltose
(FE arm) versus a placebo (PLACEBO arm) in reducing the percentage of patients who receive blood transfusions,
as well as mortality in the perioperative period of hip fracture intervention.
Methods/Design: Multicentric, phase III, randomized, controlled, double blinded, parallel groups clinical trial.
Patients > 65 years admitted to hospital with a hip fracture will be eligible to participate. Patients will be treated
with either a single dosage of i.v. ferric carboxymaltose of 1 g and subcutaneous erythropoietin (40.000 IU), or i.v.
ferric carboxymaltose and subcutaneous placebo, or i.v. placebo and subcutaneous placebo. Follow-up will be
performed until 60 days after discharge, assessing transfusion needs, morbidity, mortality, safety, costs, and health-
related quality of life. Intention to treat, as well as per protocol, and incremental cost-effectiveness analysis will be
performed. The number of recruited patients per arm is set at 102, a total of 306 patients.
Discussion: We think that this trial will contribute to the knowledge about the safety and efficacy of ferric
carboxymaltose with/without erythropoietin in preventing red-cell pack transfusions in patients with hip fracture.
ClinicalTrials.gov identifier: NCT01154491.
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Background
Hip fracture (HF) is highly prevalent in Spain, mainly
affecting the elderly. It is estimated that 0.7% of women
65 years or older will suffer a hip fracture during their
lifetime, and demographic trends predict that the
demand for care will double in the next 40 years [1-3].
A total of 4-8% of these patients will die during hospita-
lization, and fewer than 25% will regain mobility and
preserve autonomy at hospital discharge [4,5]. Socioeco-
nomic burden associated to HF is enormous (40.000
euros (57.000 US dollars)) per patient [6].
Anemia is the one of the most frequent complications
o fH F ;a r o u n do n et h i r dt oo n eh a l fo fp a t i e n t sw i l l
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transfusion has been the classical choice in treating
severe anemia of these patients [7]. Nevertheless, as
already stated, the increasing incidence of HF in this
population has also raised the need for this valuable and
scarce resource. Additionally, RCP transfusions are not
without complications [8-11]. In very old and often fra-
gile patients, these effects may involve excess morbidity
and mortality, making it necessary to develop blood-sav-
ing strategies (BSS) [9,12].
The most important factor in the development of ane-
mia is blood loss, but some other mechanisms (renal
failure, inflammation, iatrogenic hemodilution) are also
implicated, prompting the choice of different therapeutic
approaches [9,13,14]. These rely in three cornerstones:
firstly minimizing blood loss in the operating room, sec-
ondly rationalizing RCP transfusion protocols, and
thirdly enhancing bone-marrow red blood cell produc-
tion [13-16]. Although evidence that this last measure
saves RCP is weak, an increasing number of works have
demonstrated notable reductions in RPC transfusion,
nosocomial infections, hospital stay, and even survival
[14-16]. Nevertheless, some biases in the nature of said
studies could partly explain some of the obtained
results.
All these previous studies were performed using 300
to 600 mg of intravenous iron sucrose administered in a
period ranging from 2 to 6 days. Ferric carboxymaltose
(FC) has considerable advantages over iron sucrose
because it allows doses of 1 g in a single session, equiva-
lent to 1000 mg of iron sucrose. Moreover, FC also pro-
vides an excellent tolerability and safety profile [17-19].
Therefore, it is very useful in situations where quick
replacement is required as is the case of HF. It has been
used successfully in iron deficiency-, inflammatory-, and
in postpartum anemia, however there are no data on its
efficacy in HF.
Preliminary results of perioperative use of EPO in HF
are promising; however, these results suffer from bias
because trials were not randomized and/or blinded. On
the other hand, all studies were performed with iron
sucrose, so that any additional benefit related to FC can-
not be extrapolated. Therefore we have promoted and
developed a phase III clinical trial (CT) in order to defi-
nitively assess the benefit of RCP saving with the use of
EPO with/without FC in patients with HF. The main
objective of the present CT was to evaluate the efficacy
of combined treatment of i.v. ferric carboxymaltose and
erythropoietin (EPOFE arm) versus i.v. ferric carboxy-
maltose (FE arm) versus placebo (placebo arm) in redu-
cing the percentage of patients who receive blood
transfusions in the perioperative period of hip fracture
intervention.
Methods
This is a multicentric, randomized, controlled, double
blinded clinical trial of parallel groups, performed on
adult in-hospital patients admitted with an HF. The eli-
gible patients will be those admitted to the Emergency-
Traumatology Services from the moment of admission
until the moment of surgery. Inclusion and exclusion
criteria are detailed in Table 1. Once the patient is eligi-
ble, meets inclusion criteria, does not meet any exclu-
sion criteria and signs the informed consent form to
participate in the clinical trial, the investigator will pro-
ceed to randomize the patient to the intervention group,
and to perform the analytical extraction of blood count
prior to the administration of the first dose of the trial
drugs. The investigators will be responsible for having
provided appropriate information about objectives,
methods, anticipated benefits and potential risks to all
eligible patients. If the patient is unable to read or to
give consent, the legal representative must be present
during the informed consent process and the legal
representative will sign the consent form to attest that
the information contained in the form has been
explained and understood accurately and, where appro-
p r i a t e ,t og i v ec o n s e n t .T he investigator must also
explain that patients are completely free to refuse to
participate in the study or withdraw at any time for any
reason.
A randomization assignment list will be stratified by
center. The randomization list for each center will be
sent to the hospital Pharmacy Service at the time of the
drug delivery. The person responsible for clinical trials
in the Pharmacy Service will be the one responsible for
keeping the blinded assignment. The allocation and
blinding will be done by masking the syringes of EPO/
placebo and iron infusion in the Pharmacy Service of
each of the participating centers. The highest quality
standards for handling parenteral medications will be
kept for the preparation of intravenous mixtures. FC
will be performed using plastic bags and opaque infu-
sion sets.
Treatment will be administered in the three arms
detailed in Table 2: Erythropoietin + Intravenous fer-
r i cc a r b o x y m a l t o s e( E P O F EA R M ) ;P l a c e b oo fE r y t h r o -
poietin + Intravenous ferric carboxymaltose (FE
ARM); Placebo of Erythropoietin + placebo of intrave-
nous ferric carboxymaltose (PLACEBO ARM). The
trial treatment will be administered, regardless of the
arm, as soon as possible after inclusion, and always
before surgery. Patients will receive the best standard
treatment based on protocols existing in each hospital
and the best medical care from both the internal med-
icine and orthopedic teams. Neither intravenous iron
nor erythropoietin will be administered to the patient
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patients could receive complementary oral iron if it is
clinically indicated. Additionally, in clinical practice if
the hemoglobin at discharge is less than 120 g/L, and
no contraindications exits, oral iron regimen will be
prescribed to the patient. The promotor’s center (Hos-
p i t a lU n i v e r s i t a r i oV i r g e nd e lR o c í o )w i l lp r o v i d et h e
drugs for the trial, experimental and control treat-
ments. The labeling and distribution of the study
drugs will be managed by the Pharmacy Service of
Virgen del Rocío University Hospital after having
obtained the Spanish Regulatory approval for these
procedures.
Patients will be examined by the clinical support team
and the Traumatology team at every visit during the
study. The data will de classified by visit, and logged in
the Clinical Report Data Form (Figure 1).
Study visits
Clinical, analytical and exploratory data needed for the
study will be collected by the investigator. Clinical trial
visits are structured in five stages as detailed below:
-Visit 0: Screening day.
-Visit 1: In the first 24 hours postoperative period.
-Visit 2: After the first 72 hours postoperative period.
-Visit 3: The day of hospital discharge.
-Visit 4: 60 days at hospital discharge.
Withdrawal from the study
Each participant will have the right to withdraw from
the study at any time. In addition, the investigator may
remove a participant from the study at any time if it is
considered necessary for any reason including: signifi-
cant protocol deviation, significant non-compliance with
treatment regimen or study requirements, an adverse
event which requires discontinuation of the study medi-
cation or results, inability to continue to comply with
study procedures, consent withdrawn, and loss of follow
up.
All the patients leaving the study will fulfill the
described procedures of premature finalization as
described in the protocol. The analysis will be carried
out for all the patients who have received a dose of
experimental medicine or control.
Outcome measures
The primary outcome measure will be the percentage of
patients who receive red-cell transfusion during hospita-
lization, and after 60 days of hospital discharge.
Secondary outcome measures will be the following
related with efficacy, safety, HRQoL, and cost-
effectiveness
Efficacy end-points: the average number of red-cell
packs needed per patient at the end of the study, the
average number of red-cell packs needed per patient
Table 1 Inclusion and exclusion criteria for entering the PAHFRAC-01 clinical trial
INCLUSION CRITERIA EXCLUSION CRITERIA
Age ≥65 years Bone marrow diseases which could interfere in the erythropoietic process (acute or chronic myelodysplastic
syndromes or myeloproliferative diseases, and/or infiltration of the bone marrow due to solid or lymphatic
neoplasm)
Osteoporotic hip fracture requiring
surgical repair
Blood coagulation diseases or being currently treated with oral anticoagulants and/or heparin at therapeutic
doses.
Hemoglobin levels between 90-120
g/L
Documented allergy and/or previous intolerance and/or contraindication of erythropoietin use and/or
intravenous iron
Signed informed consent form Patients with rheumatoid arthritis and/or another demonstrated origin of inflammatory anemia and/or not
controlled arterial hypertension
Patients with current or previous treatment for at least 3 months, with erythropoietin or intravenous iron
Patients with chronic renal failure receiving hemodialysis or peritoneal dialysis




EPOFE ARM Single dose of 40.000 IU of erythropoietin in a pre-filled 1 ml syringe, subcutaneously.
Ferric carboxymaltose 1000 mg (two 500 mg vials diluted in a bottle of 250 ml of saline, in a plastic bag, and with an opaque
infusion system), intravenously in a 20-min infusion.
FE ARM Single dose placebo (saline) in a pre-filled 1 ml syringe, subcutaneously.
Ferric carboxymaltose 1000 mg (two 500 mg vials diluted in a bottle of 250 ml of saline, in a plastic bag, and with an opaque
infusion system), intravenously in a 20-min infusion.
PLACEBO ARM Single dose placebo (saline) in a pre-filled 1 ml syringe, subcutaneously.
Ferric carboxymaltose 1000 mg (two 500 mg vials diluted in a bottle of 250 ml of saline, in a plastic bag, and with an opaque
infusion system), intravenously in a 20-min infusion.
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at 24 and 72 hours postoperative period and at hospital
discharge, and the total number of hospitalization days.
Safety endpoints: the death rate from all causes at the
end of the study; and adverse events including the fol-
lowing clinical complications: vascular events, all kinds
of cerebrovascular accidents, acute coronary syndrome,
thrombosis, arterial embolism, heart failure, acute/
chronic exacerbation of respiratory failure, delirium,
thromboembolic disease, catheter-related phlebitis; renal
failure; infectious complications: pneumonia, urinary
tract infection, surgical-site infection; and all side effects
detailed on the EPO and FC data sheet.
HRQoL end-point: Quality of life will be assessed by
the Short form 36 version 2 (SF-36) for acute patients
[20]. This questionnaire will be administered at inclu-
sion and 60 days after hospital discharge.
Cost-effectiveness end-point: An analysis of incremen-
tal cost-effectiveness (using as a primary endpoint each
patient not requiring a transfusion, and as a secondary
endpoint every patient who survived the index admis-
sion) will be performed.
Sample size calculation
Sample size was calculated as follows:
-To obtain statistical significance in the comparison
between the i.v. iron + EPO arm compared to placebo.
The treatment arm exclusively with iron is only used in
the evaluation of results, but not in the sample size
calculation.
-To obtain a confidence level of 95% and 80% power.
-To be single sided.
-To obtain a reduction in the primary endpoint of
20% (percentage of patients who need transfusions),
which is considered as clinically significant in the litera-
ture. According to this, we would expect the percentage
of patients who need to be transfused in the placebo
group to be 60% and in the treatment group 40%.
-Sample size was calculated online using SISA http://
www.quantitativeskills.com/sisa/calculations/samsize.
htm. A total of 87 patients per arm are needed with the
foregoing conditions.
-Taking into account a percentage of drop-outs of
15% per arm, the total number of patients per arm is set
at 87 × (1/1-0.15) = 102, a total of 306 patients.
Statistical analysis
Both intention to treat (ITT) and per protocol analysis
will be performed. The ITT analysis will include all
patients who agreed to participate in the study, signed
the informed consent, and had been randomized. Per
protocol analysis will include the patients who were ran-
domized, received the dose of erythropoietin and ferric
carboxymaltose (EPOFE arm), ferric carboxymaltose (FE
arm), or placebo (PLACEBO arm), and were operated
on; excluding those who discontinued the trial, or
received a red-cell pack in a different format than speci-
fied in the protocol. Violation of the blinded assignment
will be also excluded in the per protocol analysis.
A chi-square test will be performed in order to estab-
lish the comparative analysis of the primary efficacy out-
come, secondary efficacy, safety and cost endpoints
between different arms of the study (Yates correction
and, where necessary, Fisher exact test) for qualitative
endpoints. Analysis of variance (with post-hoc test of
Tukey and T3-Dunette)/Kruskal-Wallis test will be per-
formed for quantitative variables. Differences between
groups will be quantified using 95% confidence intervals.
The cost-effectiveness analysis will be performed by
incremental cost-effectiveness method, using each
patient who did not require RCP transfusion as the pri-
mary efficacy unit; each patient surviving at discharge
and 60 days after discharge as the high efficiency unit;
and the sum of all previously recorded costs of hospita-
lization as the cost unit. The calculations will be per-
formed as follows: incremental cost-effectiveness (Euros
per unit of efficiency gains) = NNT × (cost per a) option
patient - cost per b) option patient).
All calculations will be performed using SPSS 18.0.
The threshold of statistical significance is set at p < 0.05.
Interim analysis and stopping rules
An interim analysis will be performed when half of the
patients are recruited, blinded to investigators in order
to a) detect possible imbalances between the three arms
of the trial with respect to a list of independent
Figure 1 Scheme of the clinical trial visits in the three arms.V 0
= Visit 0; S = Surgery; V1 = Visit 1 (24 hours after surgery); V2 = Visit
2 (72 hours after surgery); V3 = Visit 3 (the day of hospital
discharge); V4 = Visit 4 (60 days after hospital discharge). A = Ferric
carboximaltose + Erythropoietin; B = Ferric carboximaltose +
Placebo; C = Placebo + Placebo
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efficacy endpoint was obtained at this point in the trial.
The list of independent secondary endpoints will include
the following: age, sex, type of fracture (subcapital/inter-
trochanteric), baseline hemoglobin level and type of
surgery.
Adverse events (AE), adverse reactions (AR), and safety
issues
Definition of AE
Any untoward medical occurrence in a patient or clini-
cal investigation participant administered a medicinal
product, which does not necessarily X have a causal
relationship with this treatment (the study medication).
An AE can therefore be any unfavorable and unintended
sign (including an abnormal laboratory finding), symp-
tom or disease temporarily associated with the use of
the study medication/procedure, whether or not consid-
ered related to the study medication.
Definition of AR
All untoward and unintended responses to a medicinal
product related to any dosage. “Responses to a medic-
inal product” means that a causal relationship between a
study medication and an AE is at least a reasonable pos-
sibility, i.e., the relationship cannot be ruled out. All
cases judged by either the reporting medically qualified
professional or the sponsor as having a reasonable sus-
pected causal relationship to the study medication/pro-
cedure qualify as adverse reactions.
Definition of Serious Adverse Event (SAE)
A serious adverse event is any untoward medical occur-
rence that at any dosage, results in: death, any life-threa-
tening event, any event requiring hospitalization or
prolongation of actual hospitalization, any event result-
ing in persistent or significant disability/incapacity, the
occurrence of a congenital anomaly/birth defect, or
other important medical event (other events that may
not result in death are not life threatening, or do not
require hospitalization, may be considered a serious
adverse event when, based upon appropriate medical
judgment, the event may jeopardize the patient and may
require medical or surgical intervention to prevent one
of the outcomes listed above.
To ensure no confusion or misunderstanding of the
difference between the terms “serious” and “severe”,
which are not synonymous, the following note of clarifi-
cation is provided
The term “severe” is often used to describe the inten-
sity (severity) of a specific event (as in mild, moderate,
or severe myocardial infarction); the event itself, how-
ever, may be of relatively minor medical significance
(such as severe headache).
Definition of Serious Adverse Reaction (SAR)
An adverse event (expected or unexpected) that is both
serious and, in the opinion of the reporting investigator,
believed with reasonable probability to be due to one of
the study treatments, based on the information
provided.
Definition of Suspected Unexpected Serious Adverse
Reaction (SUSAR)
A serious adverse reaction, the nature or severity of
which is not consistent with the applicable product
information (e.g. Investigator’s Brochure for an unap-
proved investigational product or summary of product
characteristics for an approved product).
Causality and expectedness
The relationship of each adverse event to the trial medi-
cation will be determined by a medically qualified clini-
cian according to the following definitions
Related
The adverse event follows a reasonable temporal
sequence from trial medication administration. It cannot
reasonably be attributed to any other cause.
Not related
The adverse event is probably produced by the partici-
pant’s clinical state or by other modes of therapy admi-
nistered to the participant.
Procedures for recording AE
All AEs occurring during the study/or until observed by
the investigator or reported by the participant, whether
or not attributed to study medication, will be recorded
on the CRF. The following information will be recorded:
description, date of onset and end date, severity, assess-
ment of relatedness to study medication, other suspect
drug or device and action taken. Follow-up information
should be provided as necessary.
AEs considered related to the study medication as
judged by a medically qualified investigator or the
sponsor will be followed until resolution or the event
is considered stable. All related AEs that result in a
participant’s withdrawal from the study or are present
at the end of the study, should be followed up until a
satisfactory resolution occurs. It will be left to the
investigator’s clinical judgment whether or not an AE
is of sufficient severity to require the participant’s
removal from treatment. A participant may also volun-
tarily withdraw from treatment due to what he or she
p e r c e i v e sa sa ni n t o l e r a b l eA E .I fe i t h e ro ft h e s e
occurs, the participant must undergo an end of study
assessment and be given appropriate care under medi-
cal supervision until symptoms cease or the condition
becomes stable.
The relationship of AEs to the study medication will
be assessed by a medically qualified investigator.
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To ensure investigators are following the protocol, com-
plying with regulatory and Good Clinical Practice (GCP)
standards, and collecting and reporting quality data,
sponsors of clinical trials monitor the progress of clini-
cal trials performed by the investigators during the clini-
cal trial. The core components of monitoring are to
ensure patient protection and to validate integrity of the
data. Monitoring involves periodic on-site visits by
monitors each year for the duration of a study as part of
a quality process. Significant findings identified as a
result of monitoring are escalated for review by the
sponsor who may then be managed as a suspected sig-
nificant deviation. Risk assessments and evaluations are
then conducted. There are circumstances where deci-
sions have to be made with regard to taking remedial
actions, which may include notifying regulatory authori-
ties and ethics committees of any significant regulatory
and/or GCP requirements. At all times, the safety and
rights of subjects are the top priority for the trial
sponsor.
The clinical trial monitor or clinical research associate
(CRA) will verify that the data have been faithfully tran-
scribed from the medical records of patients to the CRF,
keeping the confidentiality of patients according to
Spanish data protection law. If the CRA detected a mis-
match between the CRF data and medical history, he/
she will open a query with discordant data to be
reviewed by the investigator or investigating staff. This
query should be corrected by the investigating team. It
is the responsibility of the CRA to check all the open
queries in every monitoring visit, to check if it has been
corrected and to document the corrections performed.
The documents constituting the master file of the
study will include all the documents established in the
Good Clinical Practice (CPMP/ICH/135/95). The inves-
tigator will warrant that all the people involved in the
study will respect the confidentiality of any information
on the subjects of the trial, as well as the protection of
their personal character data (according to Spanish Law
15/1999, on Protection of Personal Data, from the 13th
of December). The anonymity of the participants in the
study will be preserved at all times. Only the main
researcher of each center and the coordinator of the
study will have access to the personal information of
participants.
The study data will be transcribed onto CRF and only
include a code assigned to each patient, to provide a
patient identification code. Only investigators, pharma-
cists and nurses in the study and authorized by govern-
ment agencies, if necessary, will be able to access the
medical records of patients according to Spanish law
15/1999, on Personal Data Protection, from the 13
th of
December. This confidential information will remain the
exclusive property of the principal investigator and
investigating team, may not be disclosed to others with-
out prior written consent from the investigating coordi-
nator and the other principal investigators and may not
be used except for this study.
The information originated during the course of this
trial is also considered confidential and only to be used
by investigators in relation to the objectives of the study
and its development.
In all stages of the trial development, patient confiden-
tiality will be guaranteed under current regulations.
Once the consent form is signed, a subject code is
assigned as detailed in the pr e v i o u ss e c t i o n .T h i sc o d e
will be the only possible identification for the patient in
the CRF. The CRF consists of AutoCalc paper (original
+ copy), and will be guarded at all times in a locked
p l a c eb yt h er e s e a r c h e rr e s p onsible for the inclusion of
the patient. When the collection of clinical information
and follow-up of the subject is finished, the CRA will
take the original pages and leave a copy in the custody
of the investigator responsible for the inclusion of the
patient. Original documents and copies of CRF have to
be preserved for at least 10 years from the close-end of
the trial. All CRF data on each subject will be turned
into a database using SPSS 18.0 version, which is
encrypted and stored on external memory devices, in
the custody of the CRA and the clinical trial sponsor.
Ethic, deontological and regulatory considerations
The Investigator will ensure that this study is conducted
in accordance with the principles of the Declaration of
Helsinki, ICH Guidelines for Good Clinical Practice and
in full conformity with relevant regulations.
The protocol, informed consent form, participant
information sheet and any applicable documents will be
submitted to an appropriate Ethics Committee (EC) and
Regulatory Authority for written approval.
All substantial amendments to the original approved
documents will also be sent to an appropriate Ethics
Committee (EC) and Regulatory Authority for written
approval.
The trial staff will ensure that the participants’ anon-
ymity is maintained. The participants will be identified
only by a participant ID number on the CRF and any
electronic database. All documents will be stored
securely and only accessible by trial staff and authorized
personnel. The study will comply with the Data Protec-
tion Legislation which requires data to be anonymized
as soon as it is mandatory to do so.
Once it is established that the patient meets the selec-
tion criteria for recruitment and before starting treat-
ment, the investigator is responsible for obtaining signed
informed consent of patients participating in the study
after having provided appropriate information about
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risks. In the event that the patient is unable to read or
to give consent, the legal representative must be present
during the informed consent process and the legal
representative must sign the consent form to attest that
the information contained in the form has been
explained and understood accurately and, where appro-
priate, give consent. The investigator must also explain
that patients are completely free to refuse to participate
in the study or withdraw at any time for any reason.
Discussion
Preliminary results of perioperative use of EPO with or
without intravenous iron in HF are promising
[15,16,21]; however, these results suffer from bias
because trials were not randomized and/or blinded.
With the present CT we are trying to definitively
demonstrate the efficacy, and if possible the cost-effec-
tiveness of this clinical practice.
Human recombinant EPO has already demonstrated
benefits in cardiac, cancer, orthopedic, and bloodless sur-
gery. With respect to orthopedic surgery, its positive
impact is readily apparent in patients undergoing elective
procedures associated with substantial blood loss (those
with hemoglobin levels > 10 and ≤13 g/dl, whose risk for
transfusion is estimated to exceed 10%) [22,23]. Patients
undergoing major orthopedic surgery who receive EPO
have a nearly six-fold reduction in allogeneic transfusion
risk; this benefit extends to elderly patients undergoing
major hip or knee reconstruction, and also to more het-
erogeneous populations of patients needing total joint
arthroplasty or major hip or knee surgery [24-28]. These
data point towards the hypothesis of similar benefits in the
case of HF due to similarities in the diseases, the clinical,
anesthetic, and surgical procedures, and postoperative
care. Nevertheless, some differences make HF patients a
unique population, and results obtained in the previous
trials are difficult to extrapolate to patients with HF.
On the other hand, iron deficiency correction by oral
iron intake is always slower than the correction obtained
with parenteral formulations [29]. There are some retro-
spective studies showing positive results with the use of
iron sucrose in preventing RCP transfusions in patients
with HF [14-16]. The authors pointed out that, once
injected in vivo, the iron-carbohydrate complexes are
metabolized, the iron is released where it then binds
transferrin in the plasma, and the redundant carbohy-
drate moiety is then cleared via the liver [30]. This treat-
ment option increases the erythropoietic effect (4.5-5.5
times that of basal) of intravenous iron, which lasts 7-10
days, after which the iron is sequestered by the reticu-
loendothelial system [31]. In addition, the availability of
iron sucrose, and iron carboxymaltose, two intravenous
iron preparations with much lesser and milder side
effects than iron dextran, has renewed the interest in
these therapies [17-19,32]. In this regard, the effective-
ness of iron carboxymaltose, which has additional
advantages with respect to sucrose, in the correction of
anemia after orthopedic surgery, postpartum, as well as
in other medical conditions such as inflammatory bowel
disease, heart failure, or chronic kidney disease
[17-19,33,34], has prompted us to assess its safety and
efficacy in the present trial.
In conclusion we think that this trial will contribute
with evidence about the safety and efficacy of ferric car-
boxymaltose with or without EPO in preventing RPC
transfusions in patients with hip fracture.
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